AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.340

-0.020-0.85%

Volume:2.38M

Turnover:5.52M

Market Cap:3.03B

PE:-37.76

High:2.350

Open:2.320

Low:2.280

Close:2.360

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:0.77

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.062

EPS(LYR):-0.062

ROE:-9.86%

ROA:-4.11%

PB:3.83

PE(LYR):-37.76

Loading ...

Overview Company News Filings

Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives

Simply Wall St.

Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil

Simply Wall St.

Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline

Simply Wall St.

Mesoblast Acquires Exclusive License to Chimeric Antigen Receptor Platform; Shares Up 7%

MT Newswires Live

Australian stocks edge higher as investors focus on US-Iran talks

BUZZ-Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech

BRIEF-Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products

Stock Track | Mesoblast Soars 5.22% Intraday on Acquisition of CAR-MSC Platform with Exclusive Mayo Clinic License

Mesoblast acquires CAR-MSC platform startup, secures exclusive Mayo Clinic license

Mesoblast Acquires Chimeric Antigen Receptor (Car) Platform Technology for Precision-Enhanced Cell Products

THOMSON REUTERS

Mesoblast Ltd-Acquires Car Platform for Precision-Enhanced Cell Products

THOMSON REUTERS

Mesoblast Ltd - Obtains Worldwide Exclusive Rights to Car-MSC Ip From Mayo Clinic

THOMSON REUTERS

Mesoblast Ltd - to Incorporate Engineered Cars to Enhance Product Specificity

THOMSON REUTERS

ASX April 2026 Stocks Estimated To Be Trading Below Fair Value

Simply Wall St.

Mesoblast director Gregory George buys US$ 10.1 million common shares

Did FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?

Simply Wall St.

Mesoblast director Gregory George reports US$ 5.7 million common share purchase

Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO

Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy

Simply Wall St.

Mesoblast to webcast inaugural R&D Day outlining plan to double Ryoncil revenue

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/MSB.AU/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.34,"timestamp":1788243120000,"preClose":2.36,"halted":0,"volume":2380151,"delay":0,"changeRate":-0.00847457627118645,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.06196746707978312,"marketStatus":"Closed","change":-0.02,"latestTime":"09-01 16:12:00 AEST","open":2.32,"high":2.35,"low":2.28,"amount":5519395,"amplitude":0.029661,"askPrice":2.35,"askSize":6521,"bidPrice":2.33,"bidSize":5753,"shortable":3,"etf":0,"ttmEps":-0.06196746707978312,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":2.36,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":0.770656,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.36,"auctionPrice":2.34,"auctionVolume":330705,"auctionTime":1788243005735,"referencePrice":2.34,"referenceTime":1788243912014,"auction":3,"marketStatus":"盘后竞价","timestamp":1788243005735}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-4.11%","roe":"-9.86%","lyrEps":-0.061967,"volumeRatio":0.770656,"shares":1296862776,"dividePrice":0,"high":2.35,"amplitude":0.029661,"preClose":2.36,"low":2.28,"week52Low":1.88,"pbRate":"3.83","psRate":"18.08","week52High":3.31,"institutionHeld":0,"latestPrice":2.34,"committee":-0.062571,"eps":-0.06196746707978312,"divideRate":0,"volume":2380151,"delay":0,"ttmEps":-0.06196746707978312,"open":2.32,"prevYearClose":2.72,"prevWeekClose":2.46,"prevMonthClose":2.36,"prevQuarterClose":1.955,"fiveDayClose":2.35,"twentyDayClose":2.08,"sixtyDayClose":2.04,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2629750895","title":"Mesabi Trust (MSB) Q3 Net Margin Strengthens Bearish Dividend Coverage Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2629750895","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629750895?lang=en_us&edition=fundamental","pubTime":"2026-04-24 10:19","pubTimestamp":1776997156,"startTime":"0","endTime":"0","summary":"Mesabi Trust (MSB) has put fresh FY 2026 numbers on the table, with third quarter revenue of US$3.6 million, basic EPS of US$0.21 and net income of US$2.8 million. The trust has seen quarterly revenue move between US$4.7 million and US$6.9 million and EPS range from US$0.28 to US$0.46 over the past year of reported periods, alongside net income between US$3.6 million and US$6.1 million. This sets a clear context for the latest print. With a trailing net margin of 82.8% and earnings quality...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-msb/mesabi-trust/news/mesabi-trust-msb-q3-net-margin-strengthens-bearish-dividend","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7501","BK7508","BK7067","MSB","MSB.AU","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628762489","title":"Mesoblast (ASX:MSB) Is Up 6.1% After FDA Clears Registrational DMD Trial for Ryoncil","url":"https://stock-news.laohu8.com/highlight/detail?id=2628762489","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628762489?lang=en_us&edition=fundamental","pubTime":"2026-04-19 21:04","pubTimestamp":1776603864,"startTime":"0","endTime":"0","summary":"On 8 April 2026, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel‑L‑rknd) in 76 children with Duchenne muscular dystrophy, using time‑to‑stand at nine months as the primary endpoint.\nThis marks an expansion of Ryoncil’s use beyond steroid‑refractory acute graft‑versus‑host disease into another rare pediatric indication, leveraging its existing FDA‑approved manufacturing platform and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-is-up-61-after-fda-clears-registrational-dm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4006","BK4585","MSB.AU","BK7501","MSB","BK4588","BK7508","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628109572","title":"Mesoblast (ASX:MSB) Valuation Check As New CAR Technology License Targets Stronger Cell Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2628109572","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628109572?lang=en_us&edition=fundamental","pubTime":"2026-04-16 22:08","pubTimestamp":1776348536,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) recently secured an exclusive worldwide license to a patented chimeric antigen receptor technology from Mayo Clinic, with the goal of refining the targeting and immune effects of its mesenchymal stromal cell therapies.\nSee our latest analysis for Mesoblast.\nAt a share price of A$2.24, Mesoblast has seen a 10.89% 1 month share price return and a 10.34% 7 day share price return. Over 90 days, the share price return is a 15.15% decline, while the 3 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/mesoblast-asxmsb-valuation-check-as-new-car-technology-licen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","CAR","BK4022","BK7508","BK4230","MSB","MSB.AU","BK7501","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476087","title":"Mesoblast Acquires Exclusive License to Chimeric Antigen Receptor Platform; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476087","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476087?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:35","pubTimestamp":1776216917,"startTime":"0","endTime":"0","summary":"Mesoblast  acquired an exclusive license to a patented chimeric antigen receptor technology platform to boost the effectiveness of its products, according to a Wednesday filing with the Australian bourse.The company obtained the rights to the intellectual property developed at Mayo Clinic through the acquisition of a startup mainly formed to advance the technology, the filing said.Shares rose nearly 7% in morning trade Wednesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","MSB.AU","BK7508","BK7501","MESO","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627476272","title":"Australian stocks edge higher as investors focus on US-Iran talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2627476272","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627476272?lang=en_us&edition=fundamental","pubTime":"2026-04-15 09:30","pubTimestamp":1776216641,"startTime":"0","endTime":"0","summary":"Australian stocks edge higher as investors focus on US-Iran talks April 15 (Reuters) - Australian shares rose for a second straight session on Wednesday, with miners leading the rally, as signs that d","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nL4N40Y012:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7104","BK7511","BK7067","NST.AU","VGN.AU","BK7135","BK7507","EVN.AU","MSB.AU","BK7501","BK7095","BK7506","BK7508","BHP.AU","CBA.AU","BK7030"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627631475","title":"BUZZ-Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2627631475","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627631475?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:47","pubTimestamp":1776214056,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech** Shares of Mesoblast MSB.AX rise as much as 6% to A$2.13, post their biggest intraday pct gain since March 25** Drug maker acquires exclusive licence to patented chimeric antigen receptor  technology platform ** CAR tech for precision-enhanced augmentation of therapeutic mesenchymal lineage stromal cell products** Foundational work on the technology was developed by investigators at U.S.-based Mayo Clinic** YTD, MSB down 22.4%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nL4N40Y01C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","MSB.AU","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473739","title":"BRIEF-Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473739","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627473739?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:34","pubTimestamp":1776213242,"startTime":"0","endTime":"0","summary":"BRIEF-Mesoblast Acquires CAR Platform For Precision-Enhanced Cell ProductsApril 15  - Mesoblast Ltd MSB.AX:MESOBLAST LTD-ACQUIRES CAR PLATFORM FOR PRECISION-ENHANCED CELL PRODUCTSACQUIRES CAR PLATFORM FOR PRECISION-ENHANCED CELL PRODUCTS-MSB.AXTO INCORPORATE ENGINEERED CARS TO ENHANCE PRODUCT SPECIFICITYOBTAINS WORLDWIDE EXCLUSIVE RIGHTS TO CAR-MSC IP FROM MAYO CLINICMAYO CLINIC TO PROVIDE IN-KIND SUPPORT AND GMP MANUFACTURING FOR CAR-MSC TECHNOLOGYFurther company coverage: MSB.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUE6S1NMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","MSB.AU","MESO","BK7501","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120433271","title":"Stock Track | Mesoblast Soars 5.22% Intraday on Acquisition of CAR-MSC Platform with Exclusive Mayo Clinic License","url":"https://stock-news.laohu8.com/highlight/detail?id=1120433271","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120433271?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:18","pubTimestamp":1776212319,"startTime":"0","endTime":"0","summary":"Mesoblast Ltd's stock surged 5.22% during intraday trading on Wednesday, following a series of announcements regarding a significant strategic acquisition.The company acquired a startup holding an...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627478039","title":"Mesoblast acquires CAR-MSC platform startup, secures exclusive Mayo Clinic license","url":"https://stock-news.laohu8.com/highlight/detail?id=2627478039","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627478039?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:11","pubTimestamp":1776211877,"startTime":"0","endTime":"0","summary":"Mesoblast acquired a startup holding an exclusive worldwide license to patented CAR technology for genetically engineered mesenchymal stromal cell  products.Platform, developed at Mayo Clinic, is intended to improve MSC targeting to inflamed tissue to boost potency in inflammatory diseases.Near-term development focus includes CAR-MSC candidates for ulcerative colitis or Crohn’s disease.Mesoblast also plans CAR-MSC engineered to express CD19 for lupus nephritis and other B-cell autoimmune diseases.Consideration was paid via issuance of ASX ordinary shares.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL9tRQgt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4112","BK4585","SG9999014039.USD","BK7067","SG9999014005.SGD","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","MSB.AU","BK7501","LU2210149790.SGD","LU0314104364.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627787174","title":"Mesoblast Acquires Chimeric Antigen Receptor (Car) Platform Technology for Precision-Enhanced Cell Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2627787174","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627787174?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:10","pubTimestamp":1776211856,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nTUA4VW602:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","MSB.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627442075","title":"Mesoblast Ltd-Acquires Car Platform for Precision-Enhanced Cell Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2627442075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627442075?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:25","pubTimestamp":1776209153,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUE6S1NMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MSB.AU","BK7501","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627420766","title":"Mesoblast Ltd - Obtains Worldwide Exclusive Rights to Car-MSC Ip From Mayo Clinic","url":"https://stock-news.laohu8.com/highlight/detail?id=2627420766","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627420766?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:25","pubTimestamp":1776209153,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUE6S1NMB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","MESO","BK7501","MSB.AU","BK7508","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627207504","title":"Mesoblast Ltd - to Incorporate Engineered Cars to Enhance Product Specificity","url":"https://stock-news.laohu8.com/highlight/detail?id=2627207504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627207504?lang=en_us&edition=fundamental","pubTime":"2026-04-15 07:25","pubTimestamp":1776209153,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUE6S1NMB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","MESO","BK4139","MSB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627424768","title":"ASX April 2026 Stocks Estimated To Be Trading Below Fair Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2627424768","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627424768?lang=en_us&edition=fundamental","pubTime":"2026-04-15 03:04","pubTimestamp":1776193483,"startTime":"0","endTime":"0","summary":"The Australian stock market is experiencing a period of optimism, with the ASX 200 futures seeing a significant rise as global equities receive a boost from renewed geopolitical negotiations. Amidst this fluctuating landscape, identifying stocks that are trading below their fair value can offer potential opportunities for investors looking to capitalize on market inefficiencies.","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/10930197-main-header/1585187569107","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/10930197-main-header/1585187569107"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/retail/asx-nck/nick-scali-shares/news/asx-april-2026-stocks-estimated-to-be-trading-below-fair-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/retail/asx-nck/nick-scali-shares/news/asx-april-2026-stocks-estimated-to-be-trading-below-fair-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NCK.AU","BK7508","ABV.AU","BK7016","BK7049","BK7501","BK7067","SDR.AU","BK7153","MSB.AU","LGI.AU","CHL.AU","BK7051","BK7060","BK7078","KGN.AU","BK7107","BK7062","TPW.AU","BK7043","BET.AU","BK7135","BK7161","KSL.AU","WRK.AU","MFG.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627337437","title":"Mesoblast director Gregory George buys US$ 10.1 million common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2627337437","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627337437?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:20","pubTimestamp":1776079231,"startTime":"0","endTime":"0","summary":"Mesoblast director Gregory George reported purchases of ordinary shares, raising indirect beneficial ownership to 13,586,890 shares.Transactions were reported at prices ranging from A$ 1.41 to A$ 1.48 per share.Holdings were reported as held indirectly via James George or Grant George under power of attorney to George.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL1BFvcb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mesoblast director Gregory George buys US$ 10.1 million common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626889120","title":"Did FDA-Cleared Duchenne Trial for Ryoncil Just Shift Mesoblast's (ASX:MSB) Investment Narrative?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626889120","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626889120?lang=en_us&edition=fundamental","pubTime":"2026-04-12 04:28","pubTimestamp":1775939339,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast Limited announced that the FDA granted Investigational New Drug clearance to proceed directly to a registrational trial of Ryoncil (remestemcel-L-rknd) in 76 children with Duchenne muscular dystrophy, using time-to-stand at nine months as the primary approval endpoint.\nThis move extends the use of the first FDA-approved mesenchymal stromal cell therapy beyond steroid‑refractory pediatric graft-versus-host disease and leverages a partnership with Parent Project...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/did-fda-cleared-duchenne-trial-for-ryoncil-just-shift-mesobl","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB","BK7508","MSB.AU","BK7501","BK4585","BK4006","BK7067","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626146145","title":"Mesoblast director Gregory George reports US$ 5.7 million common share purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2626146145","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626146145?lang=en_us&edition=fundamental","pubTime":"2026-04-11 07:28","pubTimestamp":1775863711,"startTime":"0","endTime":"0","summary":"Mesoblast director Gregory George reported purchases of ordinary shares, lifting indirect beneficial ownership held through related parties.Holdings tied to James George rose to 13,586,890 ordinary shares.Holdings tied to Grant George increased to 8,324,072 ordinary shares.Purchase prices in filing ranged from A$ 1.42 to A$ 14.4 per ordinary share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL6hlBfv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mesoblast director Gregory George reports US$ 5.7 million common share purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7501","MSB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626130851","title":"Cardiff Oncology names Mani Mohindru CEO, appoints Josh Muntner CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2626130851","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626130851?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:01","pubTimestamp":1775764897,"startTime":"0","endTime":"0","summary":"Cardiff Oncology named board member Mani Mohindru as president and CEO, following her stint as interim CEO.Josh Muntner was appointed CFO effective April 6; he previously served as CFO of Imvax and Mesoblast.Ajay Aggarwal was named COO effective April 27; he most recently served as SVP and head of clinical development at Aclaris Therapeutics.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL6mHz76:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK7067","BK4585","IE00BN0W2W23.USD","MSB.AU","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU2210149790.SGD","BK7508","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","BK4007","IE00B3QW5Z07.USD","BK4139","IE00BGHQF748.EUR","NDAQ","LU2210150020.SGD","IE00BKPKM429.USD","BK7501","SG9999014039.USD","SG9999014013.SGD","BK4588","ACRS","CRDF","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626182261","title":"Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy","url":"https://stock-news.laohu8.com/highlight/detail?id=2626182261","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626182261?lang=en_us&edition=fundamental","pubTime":"2026-04-09 17:37","pubTimestamp":1775727454,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) is back in focus after the US Food and Drug Administration granted investigational new drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, a high-need pediatric indication.\nSee our latest analysis for Mesoblast.\nDespite the FDA news and Ryoncil sales updates, recent trading has been choppy, with a 90 day share price return decline of 33.88%, even as the 3 year total shareholder return stands at 119.59%. At A$2.03, recent moves suggest...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/assessing-mesoblasts-valuation-after-fda-clears-new-ryoncil","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4585","BK7508","MESO","MSB.AU","BK7501","BK4139","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625944553","title":"Mesoblast to webcast inaugural R&D Day outlining plan to double Ryoncil revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2625944553","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625944553?lang=en_us&edition=fundamental","pubTime":"2026-04-08 21:08","pubTimestamp":1775653695,"startTime":"0","endTime":"0","summary":"Mesoblast will host an R&D Day event on Wednesday, April 8, from 8:00 a.m. to 11:00 a.m. EST in New York City.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDL1xKR1D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK7067","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00BN0W2W23.USD","IE00B64PRP62.GBP","BK4585","BK4112","LU2210149790.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014013.SGD","IE00B3QW5Z07.USD","BK7501","IE00BGHQF748.EUR","SG9999014021.USD","BK4588","MSB.AU","LU2095319765.USD","BK7508","IE00BKPKM429.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":187,"code":"91000000","status":"200"}]}}